Voyager Therapeutics Stock Inks a $1.2B Agreement with Novartis

Cambridge, MA¸ January 02, 2024 (Reuters) -- Voyager Therapeutics (VYGR.O) announced a strategic collaboration with the Swiss-based pharmaceutical company Novartis (NOVN.S). Under this licensing agreement, Novartis will make an upfront payment of $100 million to Voyager. Additionally, Voyager stands to receive up to $1.2 billion upon reaching specific milestones.

Read full article here.